Early Follicular Phase Human Chorionic Gonadotropin Addition May Improve the Outcomes of In Vitro Fertilization/Intracytoplasmic Sperm Injection in Patients With "Unpredictable" Poor Response to Gonadotropin-Releasing Hormone Antagonist Protocol

被引:0
|
作者
Zhang, Chunhui [1 ]
Wu, Fangrong [1 ]
Wu, Zexuan [1 ]
Sun, Bolan [1 ]
Chen, Cheng [1 ]
Qian, Weiping [1 ]
机构
[1] Peking Univ, Reprod Med Ctr, Shenzhen Hosp, Shenzhen, Peoples R China
来源
FRONTIERS IN ENDOCRINOLOGY | 2021年 / 12卷
关键词
ovarian stimulation; unpredictable POR; in vitro fertilization; low-dose hCG; GnRH antagonist; CONTROLLED OVARIAN STIMULATION; HUMAN MENOPAUSAL GONADOTROPIN; LUTEINIZING-HORMONE; RECOMBINANT FSH; WOMEN; SUPPLEMENTATION; FERTILIZATION; GROWTH; CYCLE;
D O I
10.3389/fendo.2021.739773
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose To compare the effects of early and mid-late follicular phase administration of 150 IU of human chorionic gonadotropin (hCG) on gonadotropin-releasing hormone (GnRH) antagonist protocol in "unpredictable" poor ovarian response (POR) women undergoing in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) treatment. Methods A retrospective single-center cohort study was conducted on 67 patients with "unpredictable" POR in their first IVF/ICSI cycle receiving GnRH antagonist protocol. Patients were treated with a second IVF/ICSI cycle using the same GnRH antagonist protocol with the same starting dose of recombinant follicle-stimulating hormone (rFSH) as the first cycle; a daily dose of 150 IU of hCG was administrated on either stimulation day 1 (Group A, n = 35) or day 6 (Group B, n = 32). The number of oocytes retrieved, number of usable embryos, serum level of estradiol (E-2) on day of hCG trigger, and clinical pregnant outcomes were studied. Results The addition of 150 IU of hCG on either the first day or sixth day of stimulation increases the serum level of E-2, luteinizing hormone (LH), and hCG on the day of hCG trigger. Only the use of 150 IU of hCG on the first stimulation day improved the number of oocytes retrieved, mature of oocytes, and usable embryos, but not the addition of hCG on stimulation day 6. Implantation rate, clinical pregnancy rate, and ongoing pregnancy rate showed an increasing trend in patients receiving 150 IU of hCG in the early phase compared with mid-late phase, even thought there was no statistically significant difference. Conclusions Our study demonstrated that adding 150 IU of hCG in subsequent GnRH antagonist cycle in "unpredictable" poor responders is associated with the improvement of response to stimulation. Furthermore, early follicular phase addition of 150 IU of hCG significantly increased the number of oocytes retrieved and usable embryos than did the mid-late addition of the same dose.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Novel follicular-phase gonadotropin-releasing hormone antagonist stimulation protocol for in vitro fertilization in the poor responder
    Frankfurter, David
    Dayal, Molina
    Dubey, Anil
    Peak, Douglas
    Gindoff, Paul
    FERTILITY AND STERILITY, 2007, 88 (05) : 1442 - 1445
  • [2] Low-dose human chorionic gonadotropin may improve in vitro fertilization cycle outcomes in patients with low luteinizing hormone levels after gonadotropin-releasing hormone antagonist administration
    Propst, Anthony M.
    Hill, Micah J.
    Bates, Gordon Wright
    Palumbo, Michelle
    Van Horne, Anne K.
    Retzloff, Matthew G.
    FERTILITY AND STERILITY, 2011, 96 (04) : 898 - 904
  • [3] Dual trigger with gonadotropin-releasing hormone agonist and recombinant human chorionic gonadotropin improves in vitro fertilization outcome in gonadotropin-releasing hormone antagonist cycles
    Seval, Mehmet Murat
    Ozmen, Batuhan
    Atabekoglu, Cem
    Sukur, Yavuz Emre
    Simsir, Coskun
    Kan, Ozgur
    Sonmezer, Murat
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2016, 42 (09) : 1146 - 1151
  • [4] Comparison of luteal estradiol patch and gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation versus microdose gonadotropin-releasing hormone agonist protocol for patients with a history of poor in vitro fertilization outcomes
    Weitzman, Vanessa N.
    Engmann, Lawrence
    DiLuigi, Andrea
    Maier, Donald
    Nulsen, John
    Benadiva, Claudio
    FERTILITY AND STERILITY, 2009, 92 (01) : 226 - 230
  • [5] Recombinant human luteinizing hormone (rhLH) supplementation may improve embryo quality in in-vitro-fertilization (IVF)/intracytoplasmic sperm injection (ICSI) cycles with gonadotropin-releasing hormone (GnRH) antagonist protocol.
    Elizur, S. E.
    Hourvitz, A.
    Baum, M.
    Yinon, Y.
    Levron, J.
    Dor, J.
    FERTILITY AND STERILITY, 2006, 86 : S120 - S121
  • [6] Subtle progesterone rise in the single-dose gonadotropin-releasing hormone antagonist (cetrorelix) stimulation protocol in patients undergoing in vitro fertilization or intracytoplasmic sperm injection cycles
    Seow, Kok-Min
    Lin, Yu-Hung
    Huang, Lee-Win
    Hsieh, Bih-Chwen
    Huang, Shih-Chia
    Chen, Chin-Yu
    Chen, Pei-Hsin
    Tzeng, Chii-Ruey
    Hwang, Jiann-Loong
    GYNECOLOGICAL ENDOCRINOLOGY, 2007, 23 (06) : 338 - 342
  • [7] Microdose gonadotropin-releasing hormone agonist flare-up protocol versus multiple dose gonadotropin-releasing hormone antagonist protocol in poor responders undergoing intracytoplasmic sperm injection-embryo transfer cycle
    Kahraman, Korhan
    Berker, Bulent
    Atabekoglu, Cem Somer
    Sonmezer, Murat
    Cetinkaya, Esra
    Aytac, Rusen
    Satiroglu, Hakan
    FERTILITY AND STERILITY, 2009, 91 (06) : 2437 - 2444
  • [8] Clinical Outcomes with a Fixed Recombinant Follicle-Stimulating Hormone (rFSH)/Gonadotropin-Releasing Hormone Antagonist Protocol in a Large North American Cohort of In Vitro Fertilization/Intracytoplasmic Sperm Injection Patients.
    Boostanfar, R.
    Witjes, H.
    Mannaerts, B.
    Gordon, K.
    Mahony, M.
    FERTILITY AND STERILITY, 2010, 93 (05) : S8 - S9
  • [9] Does the addition of growth hormone to the in vitro fertilization/intracytoplasmic sperm injection antagonist protocol improve outcomes in poor responders? A randomized, controlled trial
    Bassiouny, Yasmin Ahmed
    Dakhly, Dina Mohamed Refaat
    Bayoumi, Yomna Ali
    Hashish, Nawara Mohamed
    FERTILITY AND STERILITY, 2016, 105 (03) : 697 - 702
  • [10] The benefit of individualized low-dose human chorionic gonadotropin support for high responders in gonadotropin-releasing hormone agonist-triggered in-vitro fertilization/intracytoplasmic sperm injection cycles
    Lin, Li-Te
    Tsui, Kuan-Hao
    JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2016, 79 (07) : 353 - 355